Mounjaro Warnings: What Regulators and Trial Data Actually Tell You

What the MHRA's 2026 safety update means for Mounjaro users

In January 2026, the MHRA published a Drug Safety Update covering all GLP-1 receptor agonists, including tirzepatide. The central message was about acute pancreatitis: an inflammation of the pancreas that is serious, infrequent, and can occasionally be triggered by medicines in this class. The warning asks patients and clinicians to watch for severe, persistent abdominal pain that may spread to the back, with or without vomiting. That symptom pattern warrants urgent medical attention, not a wait-and-see approach. It is worth being clear about the framing here: pancreatitis is listed as an uncommon event in the clinical data, not a common one. But because it can escalate quickly, the guidance treats it as a priority warning. If you have a history of pancreatitis or certain gallbladder conditions, your prescriber will discuss whether tirzepatide is appropriate for you at all. Other symptoms that prompt urgent review include signs of a serious allergic reaction, severe dehydration from prolonged vomiting or diarrhoea, and any sudden changes in vision if you also have diabetes. The full side-effect profile for Mounjaro covers a broader range of reactions in detail, but the pancreatitis warning is the one the MHRA singled out as the highest-priority update.

Mounjaro's specific warning for people using the contraceptive pill

This is one of the Mounjaro warnings that surprises patients most, so it is worth spelling out clearly. Tirzepatide slows gastric emptying — food and other substances move through the stomach more slowly. In practice, this can reduce how much of an oral contraceptive is absorbed into the bloodstream, particularly during the weeks when the body is adjusting to a new dose. The NHS England guidance on weight-management injections advises that women taking an oral contraceptive should use an additional non-oral method (condoms, for example) for the first four weeks of Mounjaro treatment and for four weeks after each dose increase. This is not a permanent requirement; once your dose is stable and has been for a month, the interaction risk is considered lower. The same concern applies to HRT taken as tablets: NHS England recommends considering a transdermal form (patch or gel) while on tirzepatide, and discussing this with a doctor. There is no equivalent published warning for semaglutide, which is one practical difference between the two medicines that occasionally matters to patients. If contraception is something you're navigating alongside treatment, raise it at your consultation, it is a routine question, and our prescribers hear it regularly. You can also read more about what Mounjaro is and how it works before deciding whether to go ahead.

Thyroid and cancer warnings: what the data says

Animal studies with tirzepatide showed thyroid C-cell tumours at high doses in rodents. This led to a warning in the prescribing information that has understandably prompted questions from patients. The important context is that rodents appear to have a much higher sensitivity to GLP-1 receptor stimulation in thyroid C-cells than humans do, and no increase in medullary thyroid carcinoma has been observed in the human clinical trial data. That said, the contraindication is absolute: anyone with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia type 2 (MEN2), must not use Mounjaro. Prescribers screen for this before initiating treatment. The Mounjaro thyroid warning page covers the specific evidence in more depth for readers who want to understand the biology, and the Mounjaro cancer warning page addresses the broader question of what trial data does and does not show. The Black Triangle symbol (▼) that appears on Mounjaro's packaging means the MHRA is collecting additional post-market data on the medicine, it does not mean the treatment is considered unsafe, but it does mean that reporting any suspected side effects via the Yellow Card scheme matters more than usual.

Gastrointestinal warnings and the practical day-to-day picture

The SURMOUNT-1 trial, which enrolled 2,539 adults over 72 weeks, found that nausea, diarrhoea, vomiting and constipation were the most frequently reported side effects across all doses. These effects were most pronounced after the first injection and after each dose step-up, and in most participants they settled within days to roughly two weeks. The prescribing schedule (starting at 2.5mg before moving up) exists partly to give the gut time to adjust. Even so, for some people the GI symptoms are more persistent, and there is specific guidance in the patient information leaflet about staying hydrated, eating smaller meals and knowing when to contact your clinical team. If diarrhoea is your main concern, this page on diarrhoea during Mounjaro treatment goes through what the data says about frequency and what tends to help. The broader warning here is about dehydration: prolonged vomiting or diarrhoea can stress the kidneys, so persistent symptoms are not something to push through alone. Contact your prescriber or, if symptoms are severe, seek urgent care. Some patients also notice changes in their mood during treatment, and if that is something you have experienced or are concerned about, our page on how Mounjaro can affect mood and emotional wellbeing covers what the evidence currently shows. At nume, aftercare is included as standard (seven days a week) so there is always someone to contact if something feels wrong after your pen arrives. The medicine comes via DPD in plain, unbranded packaging, tracked to your door, which means no difficult conversations on the doorstep.